News and Events

Studies of an experimental ovarian cancer therapy identify a biomarker of treatment response

A new biomarker may identify patients who can benefit from drugs that inhibit CHK1 after their ovarian cancer has become resistant to PARP inhibitors.

Remembering Miranda Leah Hanson-Baseler, an indomitable immunologist

Faced with a uterine sarcoma diagnosis at just 24, Miranda Leah Hanson-Baseler persevered through treatments for 17 years.

New analysis reveals potential effective drug combinations for treating lung cancer

Researchers compared more than 5,000 drug combinations in lung cancer cells, the results of which point to combinations that may be particularly effective in combating cancer in humans.

Aligned Blog: Mentoring Across Difference

For many people, navigating higher education and entering the workforce can be challenging but having a good mentor, especially one who considers how your background impacts your lived experience, can make a difference. In this blog, the Office of Cancer Research Capacity Building's newest team member, Sonia A. Garcia, Ph.D., writes about her experience navigating through a Ph.D. program as a first-generation Latina student and the importance of mentoring across difference.

Cells’ decision to divide is reversible

Surprising findings show that cells that are preparing to divide can return to a resting state if they lose growth signals, even after they have passed what was previously thought to be a point of no return.

Drug combination provides a one-two punch attack against colorectal cancer

Researchers have identified a drug that, when combined with TOP1 inhibitors, results in improved efficacy in human colorectal cancer models — a finding that may apply to other cancers treated with TOP1 inhibitors. The results also yield important insights into our basic understanding of DNA replication and repair.

Clinical trial researching immunotherapy for tumors with specific genetic deficiencies

Mary Frances Wedekind Malone, D.O., Assistant Research Physician in the Pediatric Oncology Branch, is researching immunotherapy for SMARCB1- and SMARCA4-deficient tumors.

Clinical trial researching therapy for recurrent respiratory papillomatosis

Scott M. Norberg, D.O., Assistant Research Physician in the Center for Immuno-Oncology, is leading a trial researching drug therapy for recurrent respiratory papillomatosis.

Clinical trial researching T-cell therapy for epithelial cancers

Scott M. Norberg, D.O., Assistant Research Physician in the Center for Immuno-Oncology, is leading a trial researching T-cell therapy for gastric, breast, cervical, lung and other types of epithelial cancers.

Targeting sugar-molecule tags to proteins in the treatment of aggressive lymphomas

CCR researchers, led by Louis M. Staudt, M.D., Ph.D., have discovered a novel approach to treating diffuse large B-cell lymphoma with potentially fewer treatment-related side effects. Their work identifies and exploits the role of sugar-molecule modifications in B-cell survival.

Breadcrumb